Mohammadizadeh Fereshteh, Nasri Farnaz
Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2023 Jun 28;12:154. doi: 10.4103/abr.abr_180_22. eCollection 2023.
p16 is a cyclin-dependent kinase inhibitor and a cardinal regulator of the cell cycle. The relationship between p16 overexpression and poor prognosis of breast cancer has been reported in some studies. This study aimed to evaluate p16 expression in breast cancer in comparison to normal breast tissue and determine the association between p16 expression and clinicopathological parameters in breast cancer.
Paraffin blocks of 110 samples were studied. These included 40 invasive breast carcinoma (tumor group) and normal tissue adjacent to the tumor (tumor control), as well as 30 normal mammoplasty specimens (normal control). Samples were from the pathology archive of Alzahra Hospital, Isfahan, Iran, from 2016 to 2020. p16 expression was studied and compared in these three groups using the immunohistochemistry technique. Moreover, the relationship between p16 expression and age, tumor size, carcinoma subtype, tumor grade, and lymph node involvement was investigated in the tumor group. SPSS version 16 was used to analyze data.
p16 expression showed a significant difference between the tumor group and the two control groups with a significantly higher expression in the tumor group. There was a significant direct relationship between the intensity of p16 expression and the number of involved lymph nodes ( < 0.001). No significant relationship was detected between p16 expression and other clinicopathological factors.
p16 seems to have a rather significant expression in breast cancer in comparison to normal breast parenchyma. However, among clinicopathological parameters, we found only a direct relationship between lymph node involvement and intensity of p16 expression.
p16是一种细胞周期蛋白依赖性激酶抑制剂，也是细胞周期的主要调节因子。一些研究报道了p16过表达与乳腺癌预后不良之间的关系。本研究旨在评估乳腺癌中p16的表达，并与正常乳腺组织进行比较，同时确定p16表达与乳腺癌临床病理参数之间的关联。
对110个样本的石蜡块进行研究。这些样本包括40例浸润性乳腺癌（肿瘤组）及肿瘤旁正常组织（肿瘤对照组），以及30例正常乳房成形术标本（正常对照组）。样本来自伊朗伊斯法罕阿尔扎赫拉医院2016年至2020年的病理档案。采用免疫组织化学技术对这三组样本中的p16表达进行研究和比较。此外，在肿瘤组中研究了p16表达与年龄、肿瘤大小、癌亚型、肿瘤分级及淋巴结受累情况之间的关系。使用SPSS 16版软件进行数据分析。
肿瘤组与两个对照组之间p16表达存在显著差异，肿瘤组中p16表达明显更高。p16表达强度与受累淋巴结数量之间存在显著正相关（<0.001）。未检测到p16表达与其他临床病理因素之间存在显著关系。
与正常乳腺实质相比，p16在乳腺癌中似乎有相当显著的表达。然而，在临床病理参数中，我们仅发现淋巴结受累与p16表达强度之间存在正相关。
